Treatment of hepatitis C in liver transplant patients: Interferon out, direct antiviral combos in

Jennifer C. Price, Norah A. Terrault – 20 January 2015 – Although chronic infection with hepatitis C virus (HCV) is the leading indication for liver transplantation in the United States, graft and patient survival rates are reduced because of HCV recurrence after transplant. Interferon‐based antiviral treatment administered either before or after transplant to prevent or treat HCV recurrence, respectively, is limited because of poor tolerability and low efficacy.

Use of model for end‐stage liver disease exceptions for donation after cardiac death graft recipients relisted for liver transplantation

Richard C. Maduka, Peter L. Abt, David S. Goldberg – 17 January 2015 – Donation after cardiac death (DCD) liver transplantation is associated with increased biliary complications and graft failure. Yet for unclear reasons, DCD recipients relisted for transplantation have lower wait‐list mortality than other retransplant candidates.

Risk factors for cytomegalovirus reactivation after liver transplantation: Can pre‐transplant cytomegalovirus antibody titers predict outcome?

Jackrapong Bruminhent, Charat Thongprayoon, Ross A. Dierkhising, Walter K. Kremers, Elitza S. Theel, Raymund R. Razonable – 17 January 2015 – Despite preexisting cytomegalovirus (CMV) immunity, CMV‐seropositive liver transplantation (LT) patients remain at risk of CMV infection. We hypothesized that the pre‐transplant CMV antibody titer correlates with the risk of CMV reactivation. We conducted a retrospective study of CMV‐seropositive LT recipients who did not receive anti‐CMV prophylaxis from 2007 to 2013.

A case of granulocyte‐colony stimulating factor/plasmapheresis–induced activation of granulocyte‐colony stimulating factor–positive hepatic progenitors in acute‐on‐chronic liver failure

Delayed hepatocellular carcinoma model for end‐stage liver disease exception score improves disparity in access to liver transplant in the United States

Julie K. Heimbach, Ryutaro Hirose, Peter G. Stock, David P. Schladt, Hui Xiong, Jiannong Liu, Kim M. Olthoff, Ann Harper, Jon J. Snyder, Ajay K. Israni, Bertram L. Kasiske, W. Ray Kim – 16 January 2015 – The current system granting liver transplant candidates with hepatocellular carcinoma (HCC) additional Model for End‐Stage Liver Disease (MELD) points is controversial due to geographic disparity and uncertainty regarding optimal prioritization of candidates. The current national policy assigns a MELD exception score of 22 immediately upon listing of eligible patients with HCC.

Subscribe to